Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC

(2016) Seble G. Kassaye et al.   CLINICAL INFECTIOUS DISEASES

Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

(2016) Nicolas A. Margot et al.   HIV CLINICAL TRIALS

Current status and prospects of HIV treatment

(2016) Tomas Cihlar et al.   Current Opinion in Virology

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

(2015) L. Marije Hofstra et al.   CLINICAL INFECTIOUS DISEASES

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds

(2015) Wan-Lin Yang et al.   PLoS Pathogens

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

(2015) Rima Kulkarni et al.   HIV CLINICAL TRIALS

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

(2014) Calvin Cohen et al.   AIDS

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity

(2014) Marieke Pingen et al.   Retrovirology

Current Perspectives on HIV-1 Antiretroviral Drug Resistance

(2014) Pinar Iyidogan et al.   Viruses-Basel

In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations

(2013) Zhufang Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110)

(2013) Danielle P. Porter et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011

(2013) D. Descamps et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

(2013) Karin J. Metzner et al.   JOURNAL OF INFECTIOUS DISEASES

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes

(2011) Vivek Jain et al.   JOURNAL OF INFECTIOUS DISEASES

Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load

(2011) Art F. Y. Poon et al.   PLoS One

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

(2010) Derrick D Goodman et al.   AIDS

Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside/Nucleotide-Resistant HIV

(2010) E. R. Lanier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation

(2009) Evguenia S Svarovskaia et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934

(2009) Nicolas A Margot et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Transmission of Drug‐Resistant HIV‐1 Is Stabilizing in Europe

(2009) Jurgen Vercauteren et al.   JOURNAL OF INFECTIOUS DISEASES

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

(2009) Diane E. Bennett et al.   PLoS One

Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations

(2008) Y. Mitsuya et al.   JOURNAL OF VIROLOGY